Use the math operators workspace to apply Price Series Division operator and other studies to Isracann Biosciences. It emphasizes relative price relationships across paired instruments while keeping volatility, risk, and performance context in view.
Most technical analysis of Isracann Biosciences help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Isracann from various momentum indicators to cycle indicators. When you analyze Isracann charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Isracann Biosciences Inc., together with its subsidiaries, cultivates and distributes medical cannabis in Israel. Isracann Biosciences Inc. was founded in 2010 and is headquartered in Vancouver, Canada. Isracann Biosciences is traded on OTC Exchange in the United States. The stock overview for Isracann Biosciences summarizes business drivers, financial profile, and market behavior. Current metrics include P/B of 9.57. Isracann Biosciences has market cap of 2.45 M, ROE of -2.53%.
Methodology
Unless otherwise specified, financial data for Isracann Biosciences is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Isracann (USA Stocks:ISCNF) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Inputs are aggregated from public filings and market reference sources and public institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR. Certain values may not reflect real-time changes. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Isracann Biosciences may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Tracking Isracann Biosciences inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.